Genmab — Maj 2014
-
dara has the potential to be backbone in all MM treatments
-
made plans for studies for north of 3500 patients - problem at skaffe dara nok!!!
-
CSFB (tror jeg nok)
-
han hedder peter og lyder dansk
-
Roche siger at mangel på brug af Chlorambucil i US hindrer Gazyva take-up
-
samme gældende for Arzerra? Jan siger still early days om det samme gælder for arzerra
-
Jan væver lidt på det her område
-
possible that gazyva impacts arzerra sales - it is likely, as expected
-
ibrutinib og idelalisb tager også deres del - men det er ikke her Jan ser markedet. Det er i kombo, hvor han ser Arzerra som stærkeste kombo-partner
-
spectacular pre-clinical studies
-
vil blive præsenteret during sumemr time
-
in major conferences
-
GEN har haft a no of interactions with regulators
-
hopefully in broad label - interactions productive
-
expects decision during summer
-
Sachin fra Kempen
-
spørger til opfattelsen af ibrutinib i markedet
-
Monoterapi med ibrutinib vil få plads i double refrac pga letheden - top oncologist siger at markedet er i komboer
-
de tror markedet bliver small molecules + cd20
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind